SGMO News and Press, Sangamo Therapeutics Inc. From 05/25/22

Shares of Graphite Bio are down some 85% from their June 2021 IPO pricing, as its first-ever clinical trial for the treatment of sickle cell disease experienced a six-month delay. The company’s potentially curative technology builds on CRISPR Therapeutics by pasting a DNA templ...

Sangamo Therapeutics (NASDAQ:SGMO) stock fell May 6 despite its Q1 results beat analysts' estimates a day ago. Q1 revenue rose +7.41% Y/Y to $28.23M. The company said the increase was mainly due to a an increase of $1M related to its collaboration with Novartis, an increase of $0.7M due to a ...

The following slide deck was published by Sangamo Therapeutics, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Sangamo Therapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation

Sangamo Therapeutics, Inc. (SGMO) Q1 2022 Earnings Conference Call May 5, 2022 16:30 ET Company Participants Louise Wilkie - Investor Relations Sandy Macrae - Chief Executive Officer Rob Schott - Head of Development Jason Fontenot - Chief Scientific Officer Prathyusha Duraibabu - Chief Financ...

Sangamo Therapeutics press release (NASDAQ:SGMO): Q1 GAAP EPS of -$0.30 beats by $0.01. Revenue of $28.23M (+7.4% Y/Y) beats by $0.94M. Cash, cash equivalents and marketable securities as of March 31, 2022 were $400.3 million, compared to $464.7 million as of December 31, 2021. Guidance for 2...

Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and first quarter 2022 financial results. “This quarter, we have continued to progres...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted eight Sangamo abstracts for presentation at the 25 th ASGCT Annual Meeting being held May 16-19, 2022, in-person in Washin...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2022 financial results after the market closes on Thursday May 5, 2022. The press release will be followed by a conference call at 4:30 ...

Sangamo Therapeutics (SGMO +8.8%) dosed the first patient in a phase 1/2 trial evaluating its  CAR-Treg cell therapy TX200 to prevent immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor. The main goal of the study, called STEADFAST, is to e...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate ...